Program
veligrotug
Also written as “Veligrotug”, “AVE1642” and “veligrotrug (LUMVOA™)”.
Its studies are mostly in Graves Ophthalmopathy · Breast Neoplasms · Multiple Myeloma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viridian Therapeutics | 51 open or running | phase 4since Sep 15, 2026 | Dec 15, 2021 | Apr 2027phase 4 · NCT07832136 |
| Sanofi | 20 open or running | phase 2since Oct 16, 2008 | Oct 16, 2008 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 16, 2008First study: phase 2 study in Breast NeoplasmsNew to SanofiSanofi · NCT00774878 · 18 enrolled · France, Italy, Spain
- Oct 29, 2010Phase 1 study in Multiple MyelomaSanofi · NCT01233895 · 26 enrolled · France, Italy
- Dec 15, 2021Viridian Therapeutics's first study: phase 3 study in Graves OphthalmopathyNew to Viridian TherapeuticsViridian Therapeutics · NCT05176639 · 113 enrolled · United States, Australia, France and more
- Aug 25, 2023Phase 3 study in Graves OphthalmopathyViridian Therapeutics · NCT06021054 · 188 enrolled · United States, Australia, France and more
- Dec 12, 2023Phase 3 study in Graves OphthalmopathyViridian Therapeutics · NCT06179875 · 139 enrolled · United States, France, Germany and more
- Apr 22, 2024Phase 3 study in Graves OphthalmopathyViridian Therapeutics · NCT06384547 · 231 enrolled · United States, Australia, France and more
- Sep 15, 2026Phase 4 study in Graves OphthalmopathyViridian Therapeutics · NCT07832136 · 30 planned · United States
Ahead
- Apr 2027Primary completion: phase 4 study in Graves OphthalmopathyViridian Therapeutics · NCT07832136
TargetBeta
“A humanized monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R/CD221) ”NCIt, by rule
“Insulin-like growth factor I receptor antagonist”ChEMBL 37, by rule
Other programs on IGF1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| teprotumumabrule | Amgen | phase 4 | 18 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| MHB018Arule | Minghui Pharmaceutical | phase 3 | 6 |
| IBI311rule | Innovent Biologics | phase 3 | 5 |
| IBI3031rule | Innovent Biologics | phase 1 | 1 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07832136Graves Ophthalmopathy · United States | 4 | Not yet recruiting | Viridian Therapeutics | Apr 2027 | 30 |
| NCT06384547Graves Ophthalmopathy · United States, Australia, France and more | 3 | Completed | Viridian Therapeutics | May 1, 2025 | 231 |
| NCT06179875Graves Ophthalmopathy · United States, France, Germany and more | 3 | Completed | Viridian Therapeutics | Apr 25, 2025 | 139 |
| NCT06021054Graves Ophthalmopathy · United States, Australia, France and more | 3 | Completed | Viridian Therapeutics | Nov 4, 2024 | 188 |
| NCT05176639Graves Ophthalmopathy · United States, Australia, France and more | 3 | Completed | Viridian Therapeutics | Jul 15, 2024 | 113 |
| NCT01233895Multiple Myeloma · France, Italy | 1 | Completed | Sanofi | Sep 2008 | 26 |
| NCT00774878Breast Neoplasms · France, Italy, Spain | 2 | Terminated | Sanofi | Nov 2010 | 18 |
How it is read
Names in the registry
- “Veligrotug”, 4 entries
- “AVE1642”, 2 entries
- “veligrotrug (LUMVOA™)”, 1 entry
Conditions, from the studies’ own filings
- Graves Ophthalmopathy, 5 studies
- Breast Neoplasms, 1 study
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.